Skip to main content

Main menu

  • Content
    • Current Issue
    • Advance Access
    • Archive
    • Supplements
      • The Challenge Initiative Platform
      • Call for Abstracts
      • The Responsive Feedback Approach
    • Topic Collections
  • For Authors
    • Instructions for Authors
    • Submit Manuscript
    • Publish a Supplement
    • Promote Your Article
    • Resources for Writing Journal Articles
  • About
    • About GHSP
    • Editorial Team
    • Advisory Board
    • FAQs
    • Instructions for Reviewers
  • Webinars
    • Local Voices Webinar
    • Connecting Creators and Users of Knowledge
    • Publishing About Programs in GHSP
  • Other Useful Sites
    • GH eLearning
    • GHJournal Search

User menu

  • My Alerts

Search

  • Advanced search
Global Health: Science and Practice
  • Other Useful Sites
    • GH eLearning
    • GHJournal Search
  • My Alerts

Global Health: Science and Practice

Dedicated to what works in global health programs

Advanced Search

  • Content
    • Current Issue
    • Advance Access
    • Archive
    • Supplements
    • Topic Collections
  • For Authors
    • Instructions for Authors
    • Submit Manuscript
    • Publish a Supplement
    • Promote Your Article
    • Resources for Writing Journal Articles
  • About
    • About GHSP
    • Editorial Team
    • Advisory Board
    • FAQs
    • Instructions for Reviewers
  • Webinars
    • Local Voices Webinar
    • Connecting Creators and Users of Knowledge
    • Publishing About Programs in GHSP
  • Alerts
  • Visit GHSP on Facebook
  • Follow GHSP on Twitter
  • RSS
  • Find GHSP on LinkedIn
COMMENTARY
Open Access

Carpe DM: The First Global Diabetes Targets

Jeremy I. Schwartz, Kaushik Ramaiya, Margo Warren, Prashant Yadav, Grace Castillo, Roshini George and Helen McGuire
Global Health: Science and Practice April 2023, 11(2):e2200403; https://doi.org/10.9745/GHSP-D-22-00403
Jeremy I. Schwartz
aSection of General Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
bUganda Initiative for Integrated Management of Non-Communicable Diseases, Kampala, Uganda.
cCoalition for Access to NCD Medicines and Products.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaushik Ramaiya
cCoalition for Access to NCD Medicines and Products.
dDepartment of Internal Medicine, Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margo Warren
cCoalition for Access to NCD Medicines and Products.
eAccess to Medicine Foundation, Amsterdam, The Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prashant Yadav
cCoalition for Access to NCD Medicines and Products.
fCenter for Global Development, Washington, DC, USA.
gTechnology and Operations Management, INSEAD, Fontainebleau, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Castillo
cCoalition for Access to NCD Medicines and Products.
hPATH, Seattle, WA, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roshini George
cCoalition for Access to NCD Medicines and Products.
hPATH, Seattle, WA, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen McGuire
cCoalition for Access to NCD Medicines and Products.
hPATH, Seattle, WA, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PreviousNext
  • Article
  • Info & Metrics
  • Comments
  • PDF
Loading

Key Messages

  • Diabetes control is hampered by global inequities in care, which the new global diabetes targets aim to address.

  • There are notable similarities and differences between the diabetes targets and the widely adopted HIV targets.

  • These targets, combined with concrete operational plans, will help the global community focus efforts toward achieving global diabetes control.

GLOBAL COVERAGE TARGETS FOR DIABETES

In May 2022, the 75th World Health Assembly adopted 5 groundbreaking global targets for diabetes mellitus (DM) for 2030.1

  1. 80% of people living with DM are diagnosed

  2. 80% of those diagnosed achieve glycemic control

  3. 80% of those diagnosed achieve blood pressure control

  4. 60% of people with DM aged 40 years or older receive statins

  5. 100% of people with type 1 DM have access to affordable insulin and blood glucose self-monitoring.

The Global Diabetes Compact, which launched in 2021 on the centennial of insulin’s discovery, encompasses these targets. The Compact’s vision is to reduce the risk of diabetes and ensure everyone diagnosed with diabetes has access to equitable, comprehensive, affordable, and quality treatment and care.2

The global prevalence of type 2 DM is expected to increase from 537 million in 2021 to 643 million in 2030 and to 783 million by 2045. The prevalence in sub-Saharan Africa will increase by 134% in that period, far more dramatically than in any other region.3 Vast global inequities shape access to quality DM prevention and care.4 Pharmaceutical access programs for DM medicines vary greatly in their reach, from less than 100 persons living with DM in some low-income countries to more than 1.6 million in some lower-middle-income countries.5 In the United States, 1 in 4 people with insulin-dependent DM ration insulin due to cost,6 a rate comparable to most low- and middle-income countries, while in other high-income countries, like the United Kingdom, cost-related insulin underuse is virtually nonexistent.7 Improving access to insulin over the next decade is expected to save more than 330,000 disability-adjusted life-years.8 The largest of these gains would be seen in sub-Saharan Africa, where most persons living with DM first come to medical attention with complications from underdiagnosis and poor glycemic control.9 Resource variability also deepens these challenges and lessens people’s ability to consistently engage in DM self-care.10 These inequities present an opportunity for global attention and focus.

Targets present quantifiable milestones to the global community and provide a focus for coalescing the efforts of multiple stakeholders. As we have seen with the widely adopted Joint United Nations Programme on HIV/AIDS “90-90-90” HIV targets,11 these targets can become ubiquitous goalposts for global, regional, and national monitoring of program quality. Targets inform policymaking and form the pillars of care cascades, such as those for HIV or hypertension.12 While the HIV targets are directed at HIV-specific indicators—diagnosis, treatment, and viral suppression—the DM targets are, appropriately, cross-cutting. Attention to blood pressure and lipid management recognizes the common risk factors underlying DM and cardiovascular disease (CVD). CVD, the leading cause of death globally,13 can occur 10–15 years earlier in persons living with DM compared to those without DM.14 While HIV has been addressed through a vertical, or disease-specific approach, driven by targeted global funding mechanisms and bolstered by a passionate global advocacy movement, the control of DM and other noncommunicable diseases must be addressed through a comprehensive strategy of integrated approaches and care delivery models. However, without similar multilateral funding to contribute to market-shaping and developing systems for the procurement of tools to diagnose, monitor, and treat DM, achieving these targets is more challenging.

The control of DM and other noncommunicable diseases must be addressed through a comprehensive strategy of integrated approaches and care delivery models.

ALIGNING TARGETS WITH OPERATIONAL PLANS TO ACHIEVE GOALS

Clear consensus-based targets, combined with aligned operational plans across infectious and noncommunicable diseases, are crucial to making progress in this arena. DM prevention, treatment, and risk reduction require coordinated resources, decisions, and actions from an array of stakeholders—donors, the private sector (including pharmaceutical companies and other health product developers and manufacturers), government, health care providers, and people living with DM. However, this vital coordination can only occur when collectively accepted targets shape concrete plans for financing, procurement, distribution, and dispensing of cost-effective DM and CVD products. One strategy—regional pooled procurement—could accelerate access to key health products. However, governments will need to look for sustainable procurement solutions, and the private sector will need to collaborate to improve access to their products. Many countries do not provide coverage for noncommunicable diseases, even within universal health coverage schemes. This poses a key challenge for access to medicines and medical devices, resulting in great financial burden for persons living with DM. It would be deceptive to anticipate that resource-constrained countries will be able to fully cover such costs. Extending the impact of universal health coverage programs requires a multisectoral, person-centered approach that includes strengthening primary health care and community health worker programs; bolstering health care worker training; simple treatment protocols; and task sharing that moves the multiple facets of prevention and management away from doctors and facilities towards other clinical staff, people living with DM by way of self-care, and the community.15

While these targets do address key clinical metrics for quality DM care and CVD risk reduction, they lack any focus on DM prevention. The World Health Organization’s “best buys” are evidence-based, cost-effective interventions that cost under $100 per disability-adjusted life-year averted in low- and middle-income countries.16 Drug therapy for those with DM and/or hypertension and a high risk of CVD is a best buy. But so too are upstream preventive efforts, including reducing physical inactivity and unhealthy diet, that are widely known to prevent or delay the onset of DM17 or even lead to its remission.18 Such prevention measures will require multisectoral approaches that could include mass media educational campaigns, reformulation of food products, and urban planning to encourage physical activity through changes to the built environment.17

CONCLUSION

We call on the global community—persons living with DM and their advocates, policymakers, pharmaceutical industry, public health and health care practitioners, and researchers—to “seize the day.” As we move forward to the September 2023 United Nations High-Level Meeting on Universal Health Coverage, let’s use the DM targets as an opportunity to drive a new generation of advocacy, policy, prevention, care, and implementation research to inform affordable, practical, locally relevant, and contextualized health service delivery solutions to reduce the risk of DM and its complications worldwide…Carpe DM!

Author contributions

JIS drafted the article. All authors provided substantive comments and edits. JIS wrote the final draft. All authors approved the final article.

Competing interests

PY serves on the Sustainability and Access Advisory Committee of Novo Nordisk.

Notes

Peer Reviewed

First published online: April 3, 2023.

Cite this article as: Schwartz JI, Ramaiya K, Warren M, et al. Carpe DM: the first global diabetes targets. Glob Health Sci Pract. 2023;11(2):e2200403. https://doi.org/10.9745/GHSP-D-22-00403

  • Received: August 20, 2022.
  • Accepted: March 7, 2023.
  • Published: April 28, 2023.
  • © Schwartz et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a copy of the license, visit https://creativecommons.org/licenses/by/4.0/. When linking to this article, please use the following permanent link: https://doi.org/10.9745/GHSP-D-22-00403

REFERENCES

  1. 1.↵
    First-ever global coverage targets for diabetes adopted at the 75th World Health Assembly. World Health Organization. May 28, 2022. Accessed March 20, 2023. https://www.who.int/news-room/feature-stories/detail/first-ever-global-coverage-targets-for-diabetes-adopted-at-the-75-th-world-health-assembly
  2. 2.↵
    The WHO Global Diabetes Compact. World Health Organization. Accessed March 20, 2023. https://www.who.int/initiatives/the-who-global-diabetes-compact
  3. 3.↵
    International Diabetes Federation (IDF). IDF Diabetes Atlas. 10th ed. IDF; 2021. Accessed March 20, 2023. https://diabetesatlas.org/atlas/tenth-edition/
  4. 4.↵
    1. Fralick M,
    2. Jenkins AJ,
    3. Khunti K,
    4. Mbanya JC,
    5. Mohan V,
    6. Schmidt MI
    . Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol 2022;18(4):199–204. doi:10.1038/s41574-021-00621-y. pmid:35039662
    OpenUrlCrossRefPubMed
  5. 5.↵
    Access to Medicine Foundation. Access to Medicine Index 2021. Access to Medicine Foundation; 2021. Accessed March 20, 2023. https://accesstomedicinefoundation.org/medialibrary/resources/613f5fb390319_Access_to_Medicine_Index_2021.pdf
  6. 6.↵
    1. Herkert D,
    2. Vijayakumar P,
    3. Luo J, et al
    . Cost-related insulin underuse among patients with diabetes. JAMA Intern Med 2019;179(1):112–114. doi:10.1001/jamainternmed.2018.5008. pmid:30508012
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pfiester E,
    2. Braune K,
    3. Thieffry A,
    4. Ballhausen H,
    5. Gajewska KA,
    6. O'Donnell S
    . Costs and underuse of insulin and diabetes supplies: findings from the 2020 T1International cross-sectional web-based survey. Diabetes Res Clin Pract 2021;179:108996. doi:10.1016/j.diabres.2021.108996. pmid:34363862
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Basu S,
    2. Yudkin JS,
    3. Kehlenbrink S, et al
    . Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol 2019;7(1):25–33. doi:10.1016/s2213-8587(18)30303-6. pmid:30470520
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Atun R,
    2. Davies JI,
    3. Gale EAM, et al
    . Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol 2017;5(8):622–667. doi:10.1016/s2213-8587(17)30181-x. pmid:28688818
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Schwartz JI,
    2. Kalyesubula R,
    3. Amstrong-Hough M,
    4. Hawley NL
    . NCD medicines and products- not just resource limited, but resource variable. Coalition For Access to NCD Medicines and Products Medium page. September 8, 2020. Accessed March 20, 2023. https://medium.com/@coalition4ncds/ncd-medicines-and-products-not-just-resource-limited-but-resource-variable-ae824f391a4b
  11. 11.↵
    1. McMahon JH,
    2. Medland N
    . 90-90-90: how do we get there? Lancet HIV 2014;1(1):e10–e11. doi:10.1016/s2352-3018(14)70017-7. pmid:26423810
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Muddu M,
    2. Tusubira AK,
    3. Sharma SK,
    4. Akiteng AR,
    5. Ssinabulya I,
    6. Schwartz JI
    . Integrated hypertension and HIV care cascades in an HIV treatment program in Eastern Uganda: a retrospective cohort study. J Aquir Immune Defic Syndr. 2019;81(5):552–561. doi:10.1097/qai.0000000000002067. pmid:31045649
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Roth GA,
    2. Mensah GA,
    3. Johnson CO, et al
    . Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. 2021 Apr 20;77(15):1958–1959]. J Am Coll Cardiol. 2020;76(25):2982–3021. doi:10.1016/j.jacc.2020.11.010. pmid:33309175
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Booth GL,
    2. Kapral MK,
    3. Fung K,
    4. Tu JV
    . Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368(9529):29–36. doi:10.1016/s0140-6736(06)68967-8. pmid:16815377
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Narasimhan M,
    2. Kapila M
    . Implications of self-care for health service provision. Bull World Health Organ 2019;97(2):76–76A. doi:10.2471/BLT.18.228890. pmid:30728611
    OpenUrlCrossRefPubMed
  16. 16.↵
    World Health Organization (WHO). Tackling NCDs: ‘Best Buys’ and Other Recommended Interventions for the Prevention and Control of Noncommunicable Diseases. WHO; 2017. Accessed March 20, 2023. https://apps.who.int/iris/handle/10665/259232
  17. 17.↵
    1. Joseph P,
    2. Leong D,
    3. McKee M, et al
    . Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res 2017;121(6):677–694. doi:10.1161/circresaha.117.308903. pmid:28860318
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Taylor R,
    2. Ramachandran A,
    3. Yancy WS,
    4. Forouhi NG
    . Nutritional basis of type 2 diabetes remission. [published correction appears in BMJ. 2021 Jul 9;374:n1752]. BMJ 2021;374:n1449. doi:10.1136/bmj.n1449. pmid:34233884
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Global Health: Science and Practice: 11 (2)
Global Health: Science and Practice
Vol. 11, No. 2
April 28, 2023
  • Table of Contents
  • About the Cover
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Global Health: Science and Practice.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Carpe DM: The First Global Diabetes Targets
(Your Name) has forwarded a page to you from Global Health: Science and Practice
(Your Name) thought you would like to see this page from the Global Health: Science and Practice web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Carpe DM: The First Global Diabetes Targets
Jeremy I. Schwartz, Kaushik Ramaiya, Margo Warren, Prashant Yadav, Grace Castillo, Roshini George, Helen McGuire
Global Health: Science and Practice Apr 2023, 11 (2) e2200403; DOI: 10.9745/GHSP-D-22-00403

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Carpe DM: The First Global Diabetes Targets
Jeremy I. Schwartz, Kaushik Ramaiya, Margo Warren, Prashant Yadav, Grace Castillo, Roshini George, Helen McGuire
Global Health: Science and Practice Apr 2023, 11 (2) e2200403; DOI: 10.9745/GHSP-D-22-00403
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Statistics from Altmetric.com

Jump to section

  • Article
    • GLOBAL COVERAGE TARGETS FOR DIABETES
    • ALIGNING TARGETS WITH OPERATIONAL PLANS TO ACHIEVE GOALS
    • CONCLUSION
    • Author contributions
    • Competing interests
    • Notes
    • REFERENCES
  • Info & Metrics
  • Comments
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Midpoint Reflections on USAID HIV Local Partner Transition Efforts
  • Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV
Show more COMMENTARY

Similar Articles

Subjects

  • Health Topics
    • Noncommunicable Diseases
US AIDJohns Hopkins Center for Communication ProgramsUniversity of Alberta

Follow Us On

  • Twitter
  • Facebook
  • LinkedIn
  • RSS

Articles

  • Current Issue
  • Advance Access Articles
  • Past Issues
  • Topic Collections
  • Most Read Articles
  • Supplements

More Information

  • Submit a Paper
  • Instructions for Authors
  • Instructions for Reviewers
  • GH Journals Database

About

  • About GHSP
  • Advisory Board
  • FAQs
  • Privacy Policy
  • Contact Us

© 2023 Creative Commons Attribution 4.0 International License. ISSN: 2169-575X

Powered by HighWire